Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oral solid medicament composition containing lafutidine

A technology of lafutidine and composition, applied in the field of oral solid pharmaceutical compositions, can solve problems such as poor stability, patient compliance and the like

Inactive Publication Date: 2009-06-24
BEIJING D VENTUREPHARM TECH DEV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Chinese patent 021359601 discloses a lafutidine injection and its preparation method. Because the injection has poor stability and patient compliance problems during use, the present invention is dedicated to developing a stable lafutidine injection with high dissolution rate. oral solid dosage form

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral solid medicament composition containing lafutidine
  • Oral solid medicament composition containing lafutidine
  • Oral solid medicament composition containing lafutidine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019]

[0020] Preparation Process:

[0021] Weigh the prescribed amount of lafutidine, lactose, and microcrystalline cellulose, mix them evenly, prepare soft materials with 10% starch slurry, make wet granules with 18 mesh, dry at 50°C-60°C, granulate, add magnesium stearate , mixed and pressed into tablets.

Embodiment 2

[0023]

[0024] Preparation Process:

[0025] Weigh the prescribed amount of lafutidine, lactose, and microcrystalline cellulose, mix them evenly, prepare soft materials with 10% starch slurry, make wet granules with 18 mesh, dry at 50°C-60°C, granulate, add butylated hydroxyanisole , magnesium stearate, mixed evenly and compressed into tablets.

Embodiment 3

[0027]

[0028] Preparation Process:

[0029] Lafutidine and Polyethylene Glycol 6000 of prescription quantity are dissolved in 70% ethanol solution, after stirring and dissolving, spin evaporated to dryness to obtain solid mixture, powdered into fine powder, then mixed with lactose, microcrystalline cellulose Mix evenly, prepare soft materials with 10% starch slurry, make wet granules with 18 mesh, dry at 50°C-60°C, granulate, add BHA and magnesium stearate, mix evenly, and press into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an oral solid medicine composition containing lafutidine, which comprises an active ingredient, namely lafutidine and salt thereof, a solid dispersant, an antioxidant and other pharmaceutical excipients, and can be used for treating peptic ulcer.

Description

Technical field: [0001] The invention relates to an oral pharmaceutical composition, in particular to an oral solid pharmaceutical composition containing lafutidine. Background technique: [0002] Gastrointestinal diseases are common and frequently-occurring diseases. In recent years, with the increase in the incidence of digestive system diseases, the proportion of drugs used for gastrointestinal diseases in the entire clinical medicine is increasing. Commonly used drugs for the treatment of peptic ulcer are ranitidine and famotidine. This year, a new H 2 Receptor antagonist - lafutidine. [0003] The chemical name of lafutidine: (±)-2-(2-furanmethylsulfinyl)-N-[4-[4-(1-piperidylmethyl)-2-pyridyloxy]-cis -2-butenyl]acetamide. This product can reduce the basal secretion of gastric acid and inhibit the secretion of gastric acid stimulated by histamine, gastrin and urethane. Compared with ranitidine and famotidine, this product has a higher effect on H 2 The blocking effec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4545A61K47/34A61K9/20A61K9/48A61P1/04A61P1/00A61K47/10A61K47/32
Inventor 岳本花
Owner BEIJING D VENTUREPHARM TECH DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com